Want to take Stockholm3?
Prostate cancer is the second most common cancer in the world, 1.4 million men are diagnosed yearly. Early detection is the key to successful treatment. Currently, a number of healthcare providers offer Stockholm3.
-
75000
Participants in clinical studies
-
100 %
More cases of aggressive cancers found
-
50 %
Fewer unnecessary biopsies
-
17-28 %
Reduced healthcare costs
Stockholm3
A3P Biomedical’s lead product is Stockholm3, a blood test that combines protein markers, genetic markers and clinical data with a proprietary algorithm in order to detect aggressive prostate cancer at an early stage.
Press releases
-
A3P Biomedical and BioAgilytix enter partnership for Stockholm3 in the USA
September 13, 2023
-
Stockholm3 combines accurate diagnosis of prostate cancer with improved health economics
August 31, 2023
-
Stockholm3 included in the American Urological Association (AUA) guidelines for early detection of prostate cancer
May 4, 2023